Suppr超能文献

氟喹诺酮类预防用药对初诊 AML 患者中性粒细胞减少性发热、感染和抗菌药物耐药性的影响。

Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.

机构信息

Monter Cancer Center, Northwell Health, Lake Success, NY.

Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside and Mount Sinai West, New York, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):903-911. doi: 10.1016/j.clml.2022.08.001. Epub 2022 Aug 7.

Abstract

INTRODUCTION

Fluoroquinolone prophylaxis is recommended during induction chemotherapy for patients with acute myeloid leukemia (AML) to reduce risk of neutropenic fever and systemic bacterial infections. We evaluated the effectiveness of primary fluoroquinolone prophylaxis in an area with high fluoroquinolone resistance.

MATERIALS AND METHODS

We performed a retrospective chart review of newly diagnosed adult AML patients who received frontline therapy at Mount Sinai Hospital in New York, NY, between 2012 and 2019. Primary outcome was development of neutropenic fever. Secondary outcomes were development of systemic bacterial infections and infections with multidrug-resistant organisms and Clostridioides difficile. Infectious outcomes were collected through 6 months after therapy initiation. We estimated the effect of fluoroquinolone prophylaxis with a time-dependent Cox proportional hazards model.

RESULTS

Of 121 included patients, 87 received antibiotic prophylaxis and 34 did not. There was no difference in baseline characteristics, although the prophylaxis group had longer neutropenia duration (median 30 vs. 23 days, P = .013). The prophylaxis group had a reduced risk of neutropenic fever (hazard ratio 0.59, P = .039). The prophylaxis group had fewer gram-positive (P = .043) and gram-negative (P = .049) bloodstream infections and fewer clinically documented infections during frontline therapy (P = .005) and follow-up (P = .026). There was no difference in incidence of C. difficile or infection with fluoroquinolone-resistant or multidrug-resistant organisms. There was no mortality difference between groups.

CONCLUSION

In an area with high fluoroquinolone resistance, primary fluoroquinolone prophylaxis in newly diagnosed AML patients reduced the risk of neutropenic fever and systemic bacterial infections without increased antimicrobial resistance. Prospective, randomized studies are needed to confirm these observations.

摘要

简介

氟喹诺酮类药物预防治疗被推荐用于急性髓系白血病(AML)患者的诱导化疗中,以降低中性粒细胞减少性发热和全身细菌感染的风险。我们评估了在氟喹诺酮类药物耐药率高的地区,氟喹诺酮类药物一级预防的有效性。

材料和方法

我们对 2012 年至 2019 年期间在纽约西奈山医院接受一线治疗的新诊断为成人 AML 患者进行了回顾性图表审查。主要结局为中性粒细胞减少性发热的发生。次要结局为全身细菌感染以及耐多药病原体和艰难梭菌感染的发生。通过治疗开始后 6 个月来收集感染性结局。我们使用时依 Cox 比例风险模型来评估氟喹诺酮类药物预防治疗的效果。

结果

在纳入的 121 例患者中,87 例接受了抗生素预防治疗,34 例未接受预防治疗。两组患者的基线特征无差异,尽管预防组的中性粒细胞减少持续时间较长(中位数 30 天 vs. 23 天,P = 0.013)。预防组的中性粒细胞减少性发热风险降低(风险比 0.59,P = 0.039)。预防组革兰阳性菌(P = 0.043)和革兰阴性菌(P = 0.049)血流感染以及一线治疗期间和随访期间(P = 0.005 和 P = 0.026)临床确诊的感染更少。氟喹诺酮类药物耐药或耐多药病原体感染的发生率无差异。两组间死亡率无差异。

结论

在氟喹诺酮类药物耐药率高的地区,新诊断的 AML 患者使用氟喹诺酮类药物一级预防可降低中性粒细胞减少性发热和全身细菌感染的风险,而不会增加抗菌药物耐药性。需要进行前瞻性、随机研究来证实这些观察结果。

相似文献

1
Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):903-911. doi: 10.1016/j.clml.2022.08.001. Epub 2022 Aug 7.
4
Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.
J Oncol Pharm Pract. 2013 Dec;19(4):291-7. doi: 10.1177/1078155212465215. Epub 2012 Nov 26.
6
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
Curr Opin Infect Dis. 2011 Dec;24(6):545-53. doi: 10.1097/QCO.0b013e32834cf054.

引用本文的文献

1
Cancer and sepsis.
Clin Sci (Lond). 2023 Jun 14;137(11):881-893. doi: 10.1042/CS20220713.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验